Patent Yard Sign in
Canadian application, no grantCanada

Method of detecting and analysing paclitaxel-mimetic compounds

CA 2454396 A1 · Owner: Barasoain Blasco, Maria Isabel · Inventors: Barasoain Blasco, Maria Isabel; Andreu Morales, Jose Manuel; Diaz Pereira, Jose Fernando

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

A large portion of cytostatics, including paclitaxel (Taxol®) and other recently-discovered substances which mimic the antitumor effects thereof have , cellular microtubules by way of a target. The present invention relates to a high-throughput homogenous analysis which is based on the use of stabilised microtubules and fluorescent taxoids and which is used to detect any substances that can substitute paclitaxel at the site where paclitaxel binds to the microtubules and that constitute potential anticancer agents.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed May 31, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 31, 2022.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 31, 2024.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledMay 31, 2002
GrantedNo grant recorded
Term endedMay 31, 2022
Patent numberCA 2454396 A1
Classification (IPC)G01N33/50 +2 more

Timeline

Timeline From CIPO dates

2003200520072009201120132015201720192021Application filedMay 31, 2002Term endedMay 31, 2022

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.